BioNTech (BNTX) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and around 16% over the past month, inviting closer scrutiny from investors.

Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. The stock rose 6.6% to $3.01 on Wednesday. Shares are ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center , positioning the company for ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...

Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...

Eli Lilly is yet to submit a formal bid to the Abivax board, French outlet La Lettre reported. The U.S. pharmaceutical giant is awaiting an indication from the French regulator on whether a bid would ...

Pfizer and BioNTech previously announced that their jointly developed COVID-19 vaccine showed over 90% effectiveness in preventing infection based on initial trial data, although scientists ...

CureVac ( ($CVAC) ) just unveiled an update. On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

The multi-month acquisition process has now entered its implementation phase. A central element is the squeeze-out of the remaining minority shareholders. Following the expiration of an additional ...

With the merger's completion on January 6, 2026, CureVac's era on the public markets will end. The focus will shift entirely to integrating its clinical candidates, particularly in cancer ...